AU2563600A - Pluripotential cells-2 - Google Patents

Pluripotential cells-2 Download PDF

Info

Publication number
AU2563600A
AU2563600A AU25636/00A AU2563600A AU2563600A AU 2563600 A AU2563600 A AU 2563600A AU 25636/00 A AU25636/00 A AU 25636/00A AU 2563600 A AU2563600 A AU 2563600A AU 2563600 A AU2563600 A AU 2563600A
Authority
AU
Australia
Prior art keywords
cell
cells
pluripotential
tissue
embryonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25636/00A
Other languages
English (en)
Inventor
Peter Andrews
Paul Kemp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercytex Ltd
Original Assignee
Intercytex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercytex Ltd filed Critical Intercytex Ltd
Publication of AU2563600A publication Critical patent/AU2563600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
AU25636/00A 1999-02-20 2000-02-18 Pluripotential cells-2 Abandoned AU2563600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9903804.4A GB9903804D0 (en) 1999-02-20 1999-02-20 Pluripotential cells-2
GB9903804 1999-02-20
PCT/GB2000/000576 WO2000049137A2 (fr) 1999-02-20 2000-02-18 Cellules-2 pluripotentes

Publications (1)

Publication Number Publication Date
AU2563600A true AU2563600A (en) 2000-09-04

Family

ID=10848084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25636/00A Abandoned AU2563600A (en) 1999-02-20 2000-02-18 Pluripotential cells-2

Country Status (7)

Country Link
EP (1) EP1153123A2 (fr)
JP (1) JP2003514509A (fr)
AU (1) AU2563600A (fr)
CA (1) CA2371900A1 (fr)
GB (1) GB9903804D0 (fr)
HK (2) HK1040741A1 (fr)
WO (1) WO2000049137A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072343A1 (en) * 2000-11-09 2004-04-15 Verma Paul John Cell reprogramming
JPWO2003027277A1 (ja) * 2001-09-21 2005-01-06 独立行政法人 科学技術振興機構 再プログラム化因子のスクリーニング方法、該方法によりスクリーニングされた再プログラム化因子および該再プログラム化因子を利用する方法、並びに、未分化融合細胞を分化させる方法および細胞、組織、臓器の製造方法
JP2004248505A (ja) * 2001-09-21 2004-09-09 Norio Nakatsuji 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造
US7704738B2 (en) 2003-12-23 2010-04-27 Cythera, Inc. Definitive endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
BRPI0706801B8 (pt) 2006-01-31 2021-05-25 Asubio Pharma Co Ltd método de purificação de cardiomiócitos ou cardiomiócitos programados derivado de células-tronco ou fetos
EP2457994A1 (fr) 2006-04-28 2012-05-30 Daiichi Sankyo Company, Limited Procédé pour l'induction de différentiation de cellules souches pluripotentes dans des cardiomyocytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9517780D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation

Also Published As

Publication number Publication date
WO2000049137A2 (fr) 2000-08-24
CA2371900A1 (fr) 2000-08-24
HK1042112A1 (zh) 2002-08-02
GB9903804D0 (en) 1999-04-14
JP2003514509A (ja) 2003-04-22
WO2000049137B1 (fr) 2001-05-17
HK1040741A1 (zh) 2002-06-21
WO2000049137A3 (fr) 2001-03-08
EP1153123A2 (fr) 2001-11-14

Similar Documents

Publication Publication Date Title
US20190225937A1 (en) Bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients and methods for making and using such a stem cell bank
Oback et al. Donor cells for nuclear cloning: many are called, but few are chosen
Hipp et al. Sources of stem cells for regenerative medicine
James et al. Contribution of human embryonic stem cells to mouse blastocysts
US8273571B2 (en) Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
CA2387506C (fr) Production gynogenetique ou androgenetique de cellules et de lignees cellulaires pluripotentes et leur utilisation dans la production de cellules et de tissus differencies
US20040120932A1 (en) In vitro-derived adult pluripotent stem cells and uses therefor
Flasza et al. Reprogramming in inter-species embryonal carcinoma–somatic cell hybrids induces expression of pluripotency and differentiation markers
Lewandowski et al. Techniques of human embryonic stem cell and induced pluripotent stem cell derivation
KR101538089B1 (ko) 배아줄기세포-유사 세포
Do et al. Reprogramming somatic gene activity by fusion with pluripotent cells
US20100233142A1 (en) Stem Cells Derived from Uniparental Embryos and Methods of Use Thereof
Muzaffar et al. Equivalency of buffalo (Bubalus bubalis) embryonic stem cells derived from fertilized, parthenogenetic, and hand-made cloned embryos
EP1513928B1 (fr) Banque de cellules souches destinees a la production de cellules pour transplantation possedant des antigenes hla correspondant a ceux des receveurs de transplant, et procedes de constitution et d'utilisation d'une telle banque de cellules souches
AU2563600A (en) Pluripotential cells-2
AU2564100A (en) Pluripotential cells-1
Serov et al. Reprogramming mediated by cell fusion technology
Tada Nuclear reprogramming: an overview
WO2003083088A2 (fr) Therapie a base de cellules souches
Tada Nuclear Reprogramming
Du et al. Developmental incompatibility of human parthenogenetic embryonic stem cells in mouse blastocysts
Maruotti et al. Faithful reprograming to pluripotency in mammals—What does nuclear transfer teach us?
Wenceslau et al. De-Differentiation of somatic cells to a pluripotent state
Page et al. Methods for Inducing Pluripotency
Goh Using mouse embryonic fibroblast (MEF) as feeder cells for production of embryonic stem cell (ESC) line in the murine and caprine/Goh Siew Ying